IL-21R expression and clinical characteristics of CLL patient samples
| No . | Age . | Previous therapy . | Interphase cytogenetics . | % CD38+ . | % IL-21Rα expression . | RMFI of IL-21Rα+cells . |
|---|---|---|---|---|---|---|
| 1 | 55 | 5 | Nullisomy 13q- (39%), | 6 | 46 | 3.89 |
| 2 | 66 | 1 | 17P- (76%) | 0 | 27.37 | 22.2 |
| 3 | 55 | 9 | 11q22.3- (93%) | 11 | 80 | 19.1 |
| 4 | 68 | 1 | Normal | 1 | 67 | 1.85 |
| 5 | 45 | 0 | 13q- (68%) | 0 | 65 | 2 |
| 6 | 50 | 0 | 11q22.3-(90%), 13q- (93%) | 22 | 60 | 4.32 |
| 7 | 57 | 10 | 11q22.3- (93%) | 5 | 19.4 | 6.07 |
| 8 | 67 | 0 | Normal | 0 | 38 | 16.8 |
| 9 | 54 | 4 | 11q22.3 (83.4%), 13q14- (92%) | 48 | 53.6 | 4.24 |
| 10 | 64 | 4 | Normal | 0 | 64.5 | 24 |
| 11 | 77 | 4 | Normal | — | 34 | 3.89 |
| 12 | 76 | 7 | 13q14- (97%), 11q22.3 (94.3%) | 13 | 49 | 21 |
| 13 | 76 | 1 | 11q22.3 (93.3%) | 95 | 30.3 | 3.5 |
| 14 | 46 | 0 | 13q14 (28.2%) | 1 | 15 | 2.1 |
| 15 | 53 | 5 | 11q23 (10%) | — | 0.31 | 4.32 |
| 16 | 72 | 5 | 11q22.3 (7.8%) | 7 | 27.1 | 21.1 |
| 17p- (7.8%) |
| No . | Age . | Previous therapy . | Interphase cytogenetics . | % CD38+ . | % IL-21Rα expression . | RMFI of IL-21Rα+cells . |
|---|---|---|---|---|---|---|
| 1 | 55 | 5 | Nullisomy 13q- (39%), | 6 | 46 | 3.89 |
| 2 | 66 | 1 | 17P- (76%) | 0 | 27.37 | 22.2 |
| 3 | 55 | 9 | 11q22.3- (93%) | 11 | 80 | 19.1 |
| 4 | 68 | 1 | Normal | 1 | 67 | 1.85 |
| 5 | 45 | 0 | 13q- (68%) | 0 | 65 | 2 |
| 6 | 50 | 0 | 11q22.3-(90%), 13q- (93%) | 22 | 60 | 4.32 |
| 7 | 57 | 10 | 11q22.3- (93%) | 5 | 19.4 | 6.07 |
| 8 | 67 | 0 | Normal | 0 | 38 | 16.8 |
| 9 | 54 | 4 | 11q22.3 (83.4%), 13q14- (92%) | 48 | 53.6 | 4.24 |
| 10 | 64 | 4 | Normal | 0 | 64.5 | 24 |
| 11 | 77 | 4 | Normal | — | 34 | 3.89 |
| 12 | 76 | 7 | 13q14- (97%), 11q22.3 (94.3%) | 13 | 49 | 21 |
| 13 | 76 | 1 | 11q22.3 (93.3%) | 95 | 30.3 | 3.5 |
| 14 | 46 | 0 | 13q14 (28.2%) | 1 | 15 | 2.1 |
| 15 | 53 | 5 | 11q23 (10%) | — | 0.31 | 4.32 |
| 16 | 72 | 5 | 11q22.3 (7.8%) | 7 | 27.1 | 21.1 |
| 17p- (7.8%) |
Surface staining of B-CLL cells: primary cell samples from 16 B-CLL patients were stained with PE-labeled mouse mAb to human IL-21Rα or a nonbinding isotype control and analyzed by flow cytometry. The percentage of cells expressing receptor was correlated with interphase cytogenetics, CD38 expression, and direct cytotoxicity mediated by IL-21, as examined by annexin+/PI+cells.
RMFI indicates relative mean fluorescent intensity; and —, not detected.